RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mineralys Therapeutics Stock

Mineralys Therapeutics ROCE 2025

Mineralys Therapeutics ROCE

-1.01

Ticker

MLYS

ISIN

US6031701013

In 2025, Mineralys Therapeutics's return on capital employed (ROCE) was -1.01, a 186.95% increase from the -0.35 ROCE in the previous year.

Mineralys Therapeutics Aktienanalyse

What does Mineralys Therapeutics do?

Mineralys Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Mineralys Therapeutics's Return on Capital Employed (ROCE)

Mineralys Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Mineralys Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Mineralys Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Mineralys Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Mineralys Therapeutics stock

What is the ROCE (Return on Capital Employed) of Mineralys Therapeutics this year?

The ROCE of Mineralys Therapeutics is -1.01 undefined this year.

How has the ROCE (Return on Capital Employed) of Mineralys Therapeutics developed compared to the previous year?

The ROCE of Mineralys Therapeutics has increased by 186.95% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Mineralys Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Mineralys Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Mineralys Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Mineralys Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Mineralys Therapeutics impact the company?

An increase in the ROCE of Mineralys Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Mineralys Therapeutics affect the company?

A decrease in ROCE of Mineralys Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Mineralys Therapeutics?

Some factors that can affect Mineralys Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Mineralys Therapeutics so important for investors?

The ROCE of Mineralys Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Mineralys Therapeutics take to improve the ROCE?

To improve the ROCE, Mineralys Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Mineralys Therapeutics pay?

Over the past 12 months, Mineralys Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mineralys Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Mineralys Therapeutics?

The current dividend yield of Mineralys Therapeutics is .

When does Mineralys Therapeutics pay dividends?

Mineralys Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mineralys Therapeutics?

Mineralys Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Mineralys Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mineralys Therapeutics located?

Mineralys Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mineralys Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mineralys Therapeutics from 7/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/2/2025.

When did Mineralys Therapeutics pay the last dividend?

The last dividend was paid out on 7/2/2025.

What was the dividend of Mineralys Therapeutics in the year 2024?

In the year 2024, Mineralys Therapeutics distributed 0 USD as dividends.

In which currency does Mineralys Therapeutics pay out the dividend?

The dividends of Mineralys Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mineralys Therapeutics

Our stock analysis for Mineralys Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mineralys Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.